ZEISS concludes fiscal year for the first time with revenue over 10 billion
- Exceptional growth with contributions from all four segments
- Expenditure in research and development amounted to 15% of revenue
- Around 43,000 employees globally, up 11% on the prior year
- Around 3.5 billion euros in investments in infrastructure planned for the next 5 years
worldwide - around 3 billion of which to be invested in Germany
- Transformation into a data- and process-driven organization

OBERKOCHEN, GERMANY, 19 December 2023
The ZEISS Group was able to continue its dynamic revenue growth with a growth rate at the very high level of the prior year. In fiscal year 2022/23 (reporting date: 30 September 2023), revenue rose to over 10 billion euros for the first time in the company's history (prior year: 8.8 billion euros, up 15%). Earnings before interest and taxes (EBIT) were also up on the previous year at 1.7 billion euros (prior year:1.6 billion euros). All four segments of the ZEISS Group contributed to this growth despite the challenging market environment.
"We can look back on another very successful fiscal year. To be able to continue this dynamic growth path in the future, we need to set the right course now. We are doing this by investing huge sums in our further development," said Dr. Karl Lamprecht, President and CEO of ZEISS. "Our success is based on our distinctive innovative strength. To ensure this continues, we have invested 15% of revenue in research and development, personnel development, and infrastructure – more than ever before.”
Press contact
Jörg Nitschke, Head of Corporate Brand, Communications and Public Affairs
Email: joerg.nitschke@zeiss.com
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.
Bertelsmann Stiftung: Growth and innovation as cornerstones of a strong de-mocracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Press release
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds28.4.2025 08:33:05 CEST | Press release
Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
EOPA Best Business Product of the Year 2025 - DYMO LetraTag 200B (Source:OPI)25.4.2025 08:00:04 CEST | Press release
DYMO® LETRATAG 200B WINS PRESTIGIOUS “BUSINESS PRODUCT OF THE YEAR” AWARD - REINFORCING RISE OF SMART ORGANIZATION
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom